

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMERIGEN PHARMACEUTICALS LIMITED and
ARGENTUM PHARMACEUTICALS LLC
Petitioners,

v.

JANSSEN ONCOLOGY, INC.

Patent Owner.

Case IPR2016-00286¹

Patent 8,822,438 B2

PATENT OWNER'S RESPONSE

¹ Case IPR2016-01317 has been joined with this proceeding.

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. SUMMARY OF ARGUMENT IN RESPONSE	2
III. CLAIM CONSTRUCTION	8
IV. THE PRIOR ART RELIED UPON BY PETITIONERS	8
A. Gerber (Ex. 1004)	8
B. Barrie (Ex. 1005)	10
C. O’Donnell (Ex. 1003)	10
V. PETITIONERS’ SCIENTIFICALLY UNSUPPORTABLE LEAP TO OBVIOUSNESS	12
A. First Scientifically Erroneous Premise In Petitioners’ Submission: Abiraterone Acetate Works the Same Way and Would Have the Same Hormonal Side Effects as Ketoconazole	13
1. Abiraterone Acetate Has a Different Mechanism of Action From Ketoconazole	13
2. O’Donnell Confirms that Abiraterone Acetate Allows Cortisol to be Made in Normal Levels in Patients, Unlike Ketoconazole	17
3. Barrie Confirms that Abiraterone Acetate Acts Differently From Ketoconazole	22
B. Second Scientifically Erroneous Premise In Petitioners’ Submission: Ketoconazole Caused Mineralocorticoid Excess, Which Would Be Expected to Occur with Abiraterone Acetate ..	23
1. There Is No Prior Art Evidence That Ketoconazole Causes Mineralocorticoid Excess.....	24
2. There Is No Prior Art Evidence That Abiraterone Acetate Would Cause Mineralocorticoid Excess.....	26

3.	Even If Mineralocorticoid Excess Was A Problem, It Would Not Be Treated With Prednisone	28
C.	Third Scientifically Erroneous Premise In Petitioners’ Submission: Petitioners Ignore Teachings in the Art Regarding Toxicity Concerns with Prednisone	29
1.	Use of Glucocorticoids Such as Prednisone Was Avoided Due to Their Many Negative Side Effects, Particularly Detrimental to Patients with mCRPC.	30
2.	The Prior Art Taught that Prednisone Could Fuel the Prostate Cancer	32
D.	Fourth Scientifically Erroneous Premise In Petitioners’ Submission: The Combination of Ketoconazole and Prednisone Was a “Safe and Effective” Treatment for Prostate Cancer	33
1.	Gerber Did Not Establish That Co-Administration of Ketoconazole and Prednisone Is a Safe and Effective Treatment for Prostate Cancer.....	34
2.	The Intervening Prior Art Between 1990 and 2006 Taught That Ketoconazole and Prednisone Therapy Was Not A Safe and Effective Treatment for Prostate Cancer	37
VI.	PETITIONERS HAVE FAILED TO MEET THEIR BURDEN OF DEMONSTRATING OBVIOUSNESS OF THE CLAIMED INVENTION	38
A.	A Correct View of the Prior Art Confirms That There Was No Motivation to Combine O’Donnell with Gerber or Barrie with Gerber.....	38
1.	O’Donnell Does Not Provide a Motivation to Use Prednisone with Abiraterone Acetate to Treat Prostate Cancer	39
2.	Barrie Does Not Provide a Motivation to Use Prednisone with Abiraterone Acetate to Treat Prostate Cancer	41
3.	Gerber Does Not Provide a Motivation to Use Prednisone with Abiraterone Acetate to Treat Prostate Cancer	43

4.	The Prior Art As a Whole Taught that, for the Clinical Use of Abiraterone Acetate, Glucocorticoid Replacement Was Not Required	43
B.	Based on the Prior Art Describing Abiraterone Acetate and Ketoconazole, a POSA Had No Reasonable Expectation of Success in Arriving at the '438 Patented Invention	45
C.	The Unpredictability of Drug Combination Therapy for the Treatment of Prostate Cancer Precludes Obviousness	49
D.	Petitioners' Obviousness Grounds Rely On Hindsight	51
VII.	OBJECTIVE INDICIA OF NONOBVIOUSNESS CONFIRM THE PATENTABILITY OF THE CLAIMS	53
A.	Skepticism and the Failure of Others	53
B.	The Claimed Invention Shows Unexpected Results	55
C.	The Claimed Invention Has Met a Long-Felt Need	59
D.	The Claimed Invention Has Achieved Significant Commercial Success	60
E.	A Nexus Exists Between the Claimed Invention and ZYTIGA®'s Commercial Success	60
VIII.	CONCLUSION	65

TABLE OF ABBREVIATIONS

Abbreviation	Definition
ACTH	Adenocorticotrophic hormone
CYP17	17 α -hydroxylase/C _{17,20} -lyase
FDA	Food and Drug Administration
ID	Institution Decision
mCRPC	Metastatic castration-resistant prostate cancer
POSA	Person of skill in the art
PSA	Prostate specific antigen

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.